Andrew Gengos - 18 May 2023 Form 3 Insider Report for Athira Pharma, Inc. (ATHA)

Role
Officer
Signature
/s/ Mark Worthington, Attorney-in-fact for Andrew Gengos
Issuer symbol
ATHA
Transactions as of
18 May 2023
Net transactions value
$0
Form type
3
Filing time
22 May 2023, 17:51:11 UTC
Previous filing
24 Feb 2022
Next filing
06 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ATHA No securities are beneficially owned 0 18 May 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ATHA No securities are beneficially owned 18 May 2023 Not applicable 0 $0.000000 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Not applicable

Remarks:

Chief Financial Officer and Chief Business Officer